Ligand Pharmaceuticals Inc. (LGND)
NASDAQ · Healthcare
Ligand Pharmaceuticals Inc. EBITDA 2009–2025
Ligand Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Ligand Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was 25.6 M, a 193.22% decrease year-over-year.
- Ligand Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2026 was 33.6 M, a 96.14% decrease year-over-year.
- Ligand Pharmaceuticals Inc. annual ebitda for 2025 was 74.8 M, a 491.92% increase from 2024.
- Ligand Pharmaceuticals Inc. annual ebitda for 2024 was 12.6 M, a 73.93% decrease from 2023.
- Ligand Pharmaceuticals Inc. annual ebitda for 2023 was 48.5 M, a 11.19% decrease from 2022.
- Ligand Pharmaceuticals Inc. annual ebitda for 2022 was 54.6 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Ligand Pharmaceuticals Inc. EBITDA — FAQ
Ligand Pharmaceuticals Inc. (LGND) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see LGND's ebitda history?
The chart and table above show Ligand Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.